123 related articles for article (PubMed ID: 12131364)
1. Calcitriol (1,25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model.
Ahmed S; Johnson CS; Rueger RM; Trump DL
J Urol; 2002 Aug; 168(2):756-61. PubMed ID: 12131364
[TBL] [Abstract][Full Text] [Related]
2. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.
Miyake H; Chi KN; Gleave ME
Clin Cancer Res; 2000 May; 6(5):1655-63. PubMed ID: 10815883
[TBL] [Abstract][Full Text] [Related]
3. Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis.
Hershberger PA; Yu WD; Modzelewski RA; Rueger RM; Johnson CS; Trump DL
Clin Cancer Res; 2001 Apr; 7(4):1043-51. PubMed ID: 11309356
[TBL] [Abstract][Full Text] [Related]
4. Nitroxide tempo, a small molecule, induces apoptosis in prostate carcinoma cells and suppresses tumor growth in athymic mice.
Suy S; Mitchell JB; Samuni A; Mueller S; Kasid U
Cancer; 2005 Mar; 103(6):1302-13. PubMed ID: 15685617
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D compounds: clinical development as cancer therapy and prevention agents.
Trump DL; Muindi J; Fakih M; Yu WD; Johnson CS
Anticancer Res; 2006; 26(4A):2551-6. PubMed ID: 16886663
[TBL] [Abstract][Full Text] [Related]
6. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
[TBL] [Abstract][Full Text] [Related]
7. RRR-alpha-vitamin E succinate potentiates the antitumor effect of calcitriol in prostate cancer without overt side effects.
Yin Y; Ni J; Chen M; Guo Y; Yeh S
Clin Cancer Res; 2009 Jan; 15(1):190-200. PubMed ID: 19118046
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor activity of calcitriol: pre-clinical and clinical studies.
Trump DL; Hershberger PA; Bernardi RJ; Ahmed S; Muindi J; Fakih M; Yu WD; Johnson CS
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):519-26. PubMed ID: 15225831
[TBL] [Abstract][Full Text] [Related]
9. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis.
Tyagi AK; Singh RP; Agarwal C; Chan DC; Agarwal R
Clin Cancer Res; 2002 Nov; 8(11):3512-9. PubMed ID: 12429642
[TBL] [Abstract][Full Text] [Related]
10. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models.
Van Laar ES; Weitman S; MacDonald JR; Waters SJ
Prostate; 2004 Apr; 59(1):22-32. PubMed ID: 14991863
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer.
Trump DL; Potter DM; Muindi J; Brufsky A; Johnson CS
Cancer; 2006 May; 106(10):2136-42. PubMed ID: 16598750
[TBL] [Abstract][Full Text] [Related]
13. The antitumor efficacy of calcitriol: preclinical studies.
Johnson CS; Muindi JR; Hershberger PA; Trump DL
Anticancer Res; 2006; 26(4A):2543-9. PubMed ID: 16886662
[TBL] [Abstract][Full Text] [Related]
14. Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models.
Xie X; Eberding A; Madera C; Fazli L; Jia W; Goldenberg L; Gleave M; Guns ES
J Urol; 2006 May; 175(5):1926-31. PubMed ID: 16600800
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer.
Chan JS; Beer TM; Quinn DI; Pinski JK; Garzotto M; Sokoloff M; Dehaze DR; Ryan CW
BJU Int; 2008 Dec; 102(11):1601-6. PubMed ID: 18782306
[TBL] [Abstract][Full Text] [Related]
16. Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits growth of PC-3 human prostate cancer xenografts in vivo.
Srivastava SK; Xiao D; Lew KL; Hershberger P; Kokkinakis DM; Johnson CS; Trump DL; Singh SV
Carcinogenesis; 2003 Oct; 24(10):1665-70. PubMed ID: 12896904
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
18. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
[TBL] [Abstract][Full Text] [Related]
19. The in vitro cytotoxic effect of mitoxantrone in combination with fludarabine or pentostatin in B-cell chronic lymphocytic leukemia.
Morabito F; Callea I; Console G; Stelitano C; Sculli G; Filangeri M; Oliva B; Musolino C; Iacopino P; Brugiatelli M
Haematologica; 1997; 82(5):560-5. PubMed ID: 9407721
[TBL] [Abstract][Full Text] [Related]
20. The combined treatment of 1,25-dihydroxyvitamin D3 and a non-steroid anti-inflammatory drug is highly effective in suppressing prostate cancer cell line (LNCaP) growth.
Gavrilov V; Steiner M; Shany S
Anticancer Res; 2005; 25(5):3425-9. PubMed ID: 16101159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
